NorthRock Partners LLC reduced its position in Danaher Co. (NYSE:DHR – Free Report) by 33.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 3,623 shares of the conglomerate’s stock after selling 1,842 shares during the period. NorthRock Partners LLC’s holdings in Danaher were worth $1,007,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently made changes to their positions in DHR. nVerses Capital LLC bought a new stake in Danaher in the 2nd quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the second quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new position in Danaher in the second quarter valued at about $51,000. Financial Connections Group Inc. acquired a new position in Danaher during the second quarter worth about $51,000. Finally, Western Pacific Wealth Management LP acquired a new stake in shares of Danaher in the 1st quarter valued at approximately $55,000. 79.05% of the stock is currently owned by institutional investors.
Danaher Price Performance
Shares of DHR traded up $0.30 during mid-day trading on Tuesday, reaching $247.48. 211,360 shares of the stock traded hands, compared to its average volume of 2,736,363. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 1 year low of $192.35 and a 1 year high of $281.70. The company has a market cap of $178.75 billion, a price-to-earnings ratio of 47.17, a price-to-earnings-growth ratio of 4.55 and a beta of 0.85. The firm has a fifty day moving average price of $266.53 and a 200 day moving average price of $260.74.
Danaher Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is currently 20.61%.
Insider Activity at Danaher
In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.90% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
DHR has been the subject of a number of research analyst reports. Evercore ISI upped their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. KeyCorp upped their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Robert W. Baird cut their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Stephens reaffirmed an “overweight” rating and issued a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus increased their target price on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $287.16.
Get Our Latest Stock Analysis on DHR
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- What Does Downgrade Mean in Investing?
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
- Top Stocks Investing in 5G Technology
- NXP Semiconductors Nears Rock Bottom: A Buy Signal Is Expected
- The 3 Best Blue-Chip Stocks to Buy Now
- NVIDIA, Sherwin-Williams Join the Dow: What Investors Should Know
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.